{"id":"coliriobcn070660","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Limited public information is available on the specific mechanism of action for COLIRIOBCN070660. As a BCN Peptides candidate in phase 2, it likely represents a peptide-based therapeutic approach, but the exact molecular target and mechanistic details require access to proprietary development data or clinical trial registries.","oneSentence":"COLIRIOBCN070660 is a peptide-based therapeutic candidate developed by BCN Peptides, currently in phase 2 clinical development.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:08:29.533Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01726075","phase":"PHASE2, PHASE3","title":"Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy","status":"COMPLETED","sponsor":"BCN Peptides","startDate":"2013-02","conditions":"Diabetic Retinopathy","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Somatostatin eye drops"],"phase":"phase_2","status":"active","brandName":"COLIRIOBCN070660","genericName":"COLIRIOBCN070660","companyName":"BCN Peptides","companyId":"bcn-peptides","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}